New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine

Jacqueline Larouche; Carlos A Aguilar

doi:10.1016/j.tibtech.2018.11.003

New Technologies To Enhance In Vivo Reprogramming for Regenerative Medicine

Trends Biotechnol. 2019 Jun;37(6):604-617. doi: 10.1016/j.tibtech.2018.11.003. Epub 2018 Dec 6.

Authors

Jacqueline Larouche¹, Carlos A Aguilar²

Affiliations

¹ Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
² Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA; Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI, USA. Electronic address: caguilar@umich.edu.

PMID: 30527703
DOI: 10.1016/j.tibtech.2018.11.003

Abstract

Cellular identity and state are determined by a collection of molecular components that are specified during development and stabilized thereafter to maintain and protect tissue functions. Alteration of the molecular elements (gene expression program and chromatin state) as a result of disease or age can induce somatic cells to assume different identities or modulate functions. Therapeutic use of this technique, called 'cellular reprogramming', is very promising for regenerative medicine, but implementation of reprogramming-based strategies in vivo has been precluded by technological and safety limitations. Recent advances in transcriptional control and improved transmembrane delivery strategies now offer exciting potential to more efficiently reprogram cell fates as well as to control the reprogramming timeline and scale of delivery to improve safety.

Keywords: CRISPR; chromatin; nanomaterials; synthetic biology; tissue repair; transcription.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
CRISPR-Cas Systems
Cellular Reprogramming*
Gene Editing
Humans
Mice
Nanomedicine
Regenerative Medicine*
Synthetic Biology